Vanderlei Segatelli1, Ebe Christie de Oliveira2, Ilka F S F Boin3, Elaine Cristina Ataide4, Cecilia Amelia F Escanhoela5. 1. Department of Pathology, Hospital Albert Einstein, Avenida Albert Einstein, 627, Morumbi, São Paulo, SP, 05652-900, Brazil. v.segate@hotmail.com. 2. Department of Pathology, Hospital Albert Einstein, Avenida Albert Einstein, 627, Morumbi, São Paulo, SP, 05652-900, Brazil. 3. Unit of Liver Transplantation, Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil. 4. Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil. 5. Department of Pathology, Faculty of Medical Science, UNICAMP, Campinas, SP, Brazil.
Abstract
PURPOSE: The progression of hepatocellular carcinoma (HCC) is multifactorial and angiogenesis plays a fundamental role, mainly because HCC is a highly vascularized tumor. METHODS: In this study, we determined microvessel density (MVD) using the immunohistochemical markers, CD34 and CD105 (Endoglin), in 44 hepatectomy specimens, encompassing 44 malignant nodules (HCC), 44 regenerative nodules (RN), and 15 dysplastic nodules (DN). The evaluation included the determination of MVD in all nodules. For statistical analysis, a descriptive analysis was carried out using measurements of position and dispersion for continuous variables; ANOVA was used to compare between groups, considering p < 0.05 as statistically significant. RESULTS: We observed a significant difference when comparing CD34 and CD105 immunoexpression in HCC, DN, and RN. CD105 was predominantly expressed in the peripheral regions in HCC, with mean MVD scores of 6.2 ± 4.1 and 10.7 ± 4.4 at the center and periphery of the nodules, respectively, with significant differences between groups (p < 0.0001). CD34 had higher mean MVD scores than CD105 in HCC, with a more uniform positivity pattern. CD105 immunoexpression in DN exhibited a pattern similar to HCC. However, in RN, CD105 exhibited a higher MVD score in the central portion of the nodules. CD105 was expressed in a subset of newly formed microvessels in HCC and demonstrated an elevated mean MVD in cirrhotic or regenerative nodules. CONCLUSIONS: MVD determined by CD34 and CD105 expression may be used as an additional parameter to distinguish benign from malignant liver nodules.
PURPOSE: The progression of hepatocellular carcinoma (HCC) is multifactorial and angiogenesis plays a fundamental role, mainly because HCC is a highly vascularized tumor. METHODS: In this study, we determined microvessel density (MVD) using the immunohistochemical markers, CD34 and CD105 (Endoglin), in 44 hepatectomy specimens, encompassing 44 malignant nodules (HCC), 44 regenerative nodules (RN), and 15 dysplastic nodules (DN). The evaluation included the determination of MVD in all nodules. For statistical analysis, a descriptive analysis was carried out using measurements of position and dispersion for continuous variables; ANOVA was used to compare between groups, considering p < 0.05 as statistically significant. RESULTS: We observed a significant difference when comparing CD34 and CD105 immunoexpression in HCC, DN, and RN. CD105 was predominantly expressed in the peripheral regions in HCC, with mean MVD scores of 6.2 ± 4.1 and 10.7 ± 4.4 at the center and periphery of the nodules, respectively, with significant differences between groups (p < 0.0001). CD34 had higher mean MVD scores than CD105 in HCC, with a more uniform positivity pattern. CD105 immunoexpression in DN exhibited a pattern similar to HCC. However, in RN, CD105 exhibited a higher MVD score in the central portion of the nodules. CD105 was expressed in a subset of newly formed microvessels in HCC and demonstrated an elevated mean MVD in cirrhotic or regenerative nodules. CONCLUSIONS: MVD determined by CD34 and CD105 expression may be used as an additional parameter to distinguish benign from malignant liver nodules.
Authors: Augusto Villanueva; Philippa Newell; Derek Y Chiang; Scott L Friedman; Josep M Llovet Journal: Semin Liver Dis Date: 2007-02 Impact factor: 6.115
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: Roberta W C Pang; Jae Won Joh; Philip J Johnson; Morito Monden; Timothy M Pawlik; Ronnie T P Poon Journal: Ann Surg Oncol Date: 2008-01-31 Impact factor: 5.344
Authors: Wolfgang Kratzer; Melanie Güthle; Felix Dobler; Thomas Seufferlein; Tilmann Graeter; Julian Schmidberger; Thomas Fe Barth; Jochen Klaus Journal: Quant Imaging Med Surg Date: 2022-03
Authors: Ciprian Roi; Pușa Nela Gaje; Raluca Amalia Ceaușu; Alexandra Roi; Laura Cristina Rusu; Eugen Radu Boia; Simina Boia; Ruxandra Elena Luca; Mircea Riviș Journal: J Clin Med Date: 2022-05-13 Impact factor: 4.964